BioCentury | Sep 7, 2015
Clinical News

MRX-I: Phase II data

...MRX-I to treat acute bacterial skin and skin structure infections (ABSSSIs). In 2012, MicuRx and Shanghai Zhangjiang Biomedical Industry Venture Capital...
BioCentury | Jan 6, 2014
Clinical News

MRX-I: Phase II started

...and 800 mg oral MRX-I vs. linezolid in about 200 patients. In 2012, MicuRx and Shanghai Zhangjiang Biomedical Industry Venture Capital...
BioCentury | Aug 22, 2013
Financial News

MicuRx raises $25 million in B round

..."shortly" and a Phase II trial in the U.S. in 2H14. Last year, MicuRx and Shanghai Zhangjiang Biomedical Industry Venture Capital...
BioCentury | Oct 29, 2012
Company News

MicuRx deal

...MicuRx and Shanghai Zhangjiang Biomedical Industry Venture Capital launched Shanghai MengKe Pharmaceuticals Inc., a JV to develop and commercialize MicuRx's antibiotic...
Items per page:
1 - 4 of 4
BioCentury | Sep 7, 2015
Clinical News

MRX-I: Phase II data

...MRX-I to treat acute bacterial skin and skin structure infections (ABSSSIs). In 2012, MicuRx and Shanghai Zhangjiang Biomedical Industry Venture Capital...
BioCentury | Jan 6, 2014
Clinical News

MRX-I: Phase II started

...and 800 mg oral MRX-I vs. linezolid in about 200 patients. In 2012, MicuRx and Shanghai Zhangjiang Biomedical Industry Venture Capital...
BioCentury | Aug 22, 2013
Financial News

MicuRx raises $25 million in B round

..."shortly" and a Phase II trial in the U.S. in 2H14. Last year, MicuRx and Shanghai Zhangjiang Biomedical Industry Venture Capital...
BioCentury | Oct 29, 2012
Company News

MicuRx deal

...MicuRx and Shanghai Zhangjiang Biomedical Industry Venture Capital launched Shanghai MengKe Pharmaceuticals Inc., a JV to develop and commercialize MicuRx's antibiotic...
Items per page:
1 - 4 of 4